Medy-Tox Inc. (086900.KQ)
- Previous Close
164,000.00 - Open
164,000.00 - Bid 167,900.00 x --
- Ask 168,000.00 x --
- Day's Range
162,600.00 - 170,500.00 - 52 Week Range
112,100.00 - 218,000.00 - Volume
72,503 - Avg. Volume
63,487 - Market Cap (intraday)
1.107T - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield 4,400.00 (2.68%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
218,000.00
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.
www.medytox.comRecent News: 086900.KQ
View MorePerformance Overview: 086900.KQ
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 086900.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 086900.KQ
View MoreValuation Measures
Market Cap
1.08T
Enterprise Value
1.10T
Trailing P/E
68.99
Forward P/E
30.40
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.12
Price/Book (mrq)
2.32
Enterprise Value/Revenue
4.82
Enterprise Value/EBITDA
28.10
Financial Highlights
Profitability and Income Statement
Profit Margin
7.42%
Return on Assets (ttm)
2.07%
Return on Equity (ttm)
3.38%
Revenue (ttm)
228.62B
Net Income Avi to Common (ttm)
15.98B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
59.51B
Total Debt/Equity (mrq)
17.06%
Levered Free Cash Flow (ttm)
25.14B